How to boost preclinical success with our neuromap

📈 XORTX Therapeutics Inc.: 30-second brief for investors XORTX Therapeutics Inc. (Nasdaq: XRTX) is moving its gout program toward a U.S. approval filing in about 12 months, targeting patients who cannot tolerate allopurinol. Key de-risking steps are in place: FDA feedback received in April, patient study completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology News #XRTX #BiotechStocks #Gout #KidneyDisease #Investing

📈 XORTX Therapeutics Inc.: 30-second brief for investors XORTX Therapeutics Inc. (Nasdaq: XRTX) is moving its gout program toward a U.S. approval filing in about 12 months, targeting patients who cannot tolerate allopurinol. Key de-risking steps are in place: FDA feedback received in April, patient study completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology News #XRTX #BiotechStocks #Gout #KidneyDisease #Investing

📈 XORTX Therapeutics Inc.: 30-second brief for investors XORTX Therapeutics Inc. (Nasdaq: XRTX) is moving its gout program toward a U.S. approval filing in about 12 months, targeting patients who cannot tolerate allopurinol. Key de-risking steps are in place: FDA feedback received in April, patient study completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology News #XRTX #BiotechStocks #Gout #KidneyDisease #Investing

RNAi Looked Doomed to Fail — Until Alnylam’s Science Chief Found a Way In the early days of RNAi drug research, Kevin Fitzgerald faced plenty of doubters. The odds were stacked against the newly blooming technology, and one colleague called the effort “career suicide.” But Fitzgerald — who at the time was a group leader in genomics at Bristol Myers Squibb and is now chief scientific officer at Alnylam Pharmaceuticals — jumped at a chance to see what RNA interference could do. The move paid off. Today, Alnylam has four drugs on the market using the RNAi technology that began as a glimmer in the eyes of scientists like Fitzgerald. And with a massive pipeline that spans a wide breadth of human disease, the company has embarked on an ambitious goal to “unlock every major tissue for RNAi therapeutics by 2030,” according to the company. https://lnkd.in/g-a4fxyd #aspenalert #biotech #bioprocess

🧬 Eli Lilly and Company again makes headlines, this time with NVIDIA to build the "most powerful" supercomputer pharma has ever seen 😮 More in today's TLDR Biotech including: 📈 Novartis Q3 revenue rises 8% to $13.9B as new drugs offset Entresto generic competition 🚀 Zag Bio debuts with $80M Series A to develop thymus-targeted autoimmune therapies ✅ Bristol Myers Squibb and Cabaletta Bio's resecabtagene autoleucel CAR-T shows remissions in Ph1/2 systemic lupus erythematosus trial 💯 Merck's Welireg belzutifan plus Keytruda shows Ph3 success in clear cell renal cell carcinoma adjuvant treatment 🤖 Mark Cuban Cost Plus Drug Company, PBC + Medchat·ai partner on AI agents for online pharmacy customer support For all the news, check out the full (free) TLDR Biotech newsletter here: https://lnkd.in/ecQQPf8Y ---------------------------------------- One skimmable email per day to keep up with biotech and pharma ➡️ https://lnkd.in/gh68uhTQ Big thanks to SciLeads for being today's sponsor - they're the all-in-one database for scientific lead generation. Start your free trial here 👉 https://lnkd.in/eHpvUNiY

Hear from Megan Sharma (Sr. Scientist at Johnson & Johnson Innovative Medicine) how she uses SCIEX CE-SDS and icIEF-UV/MS workflows to determine the overall purity of a molecule at earlier stages of the drug development pipeline. https://lnkd.in/e-XhTKtA

Hear from Megan Sharma, Sr. Scientist at Johnson & Johnson Innovative Medicine, on how she uses SCIEX CE-SDS and icIEF-UV/MS workflows to evaluate the overall purity of a molecule during early drug development stages. I can't wait to see what she accomplishes with the new BioPhase with NFD. https://lnkd.in/e-XhTKtA

Where does a CAR-T cell stop being a drug substance and start being a drug product? In cell and gene therapy manufacturing, that distinction isn’t just semantics — it defines how you validate, control, and ultimately deliver a safe, potent therapy to patients. Understanding where “substance” ends and “product” begins can mean the difference between rework and readiness. 💡 In our latest F2i Partners article, we break down how this distinction shapes validation strategy — from aseptic qualification to analytical method bridging. 👉 Read more: https://lnkd.in/g3AzDwh3 #CellTherapy #GeneTherapy #Validation #Biomanufacturing #GMP #QualityByDesign #F2iPartners

AI foundation models are transforming how we approach drug discovery, from identifying novel targets to designing therapeutics that would be impossible to find through traditional methods 💊 Our co-founder and CIO Brendan Frey will be speaking at TIDES: Oligonucleotides and Peptide Therapeutics this week on "AI's Next Frontier in Pharma: Foundation Models." He'll share how AI is driving target discovery and drug development, and discuss the opportunities and challenges ahead. What sessions are you most excited to tune into this week?  https://lnkd.in/dz6vezEV #TIDESEurope #DeepGenomics #TechBio #DrugDiscovery 

Quality assurance in biomanufacturing and clinical research is only as good as the cells you can see and what you can detect before failures happen. Deepcell enables 𝗹𝗮𝗯𝗲𝗹-𝗳𝗿𝗲𝗲, 𝗿𝗲𝗮𝗹-𝘁𝗶𝗺𝗲 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗼𝗳 𝗰𝗲𝗹𝗹 𝘀𝗵𝗮𝗽𝗲, 𝘁𝗲𝘅𝘁𝘂𝗿𝗲 𝗮𝗻𝗱 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 during routine cell culture. In a recent webinar Dr. Jeanne Rivera from UK National Measurement Laboratory (NML) at LGC shared that by continuously monitoring live-cell morphology with Deepcell's REM-i platform they can: 🔍 Detect 𝘀𝗲𝗻𝗲𝘀𝗰𝗲𝗻𝗰𝗲-𝗮𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝗺𝗼𝗿𝗽𝗵𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 🔄 Track 𝗽𝗮𝘀𝘀𝗮𝗴𝗲-𝗱𝗲𝗽𝗲𝗻𝗱𝗲𝗻𝘁 𝗱𝗿𝗶𝗳𝘁 ⚠️ Spot 𝗲𝗮𝗿𝗹𝘆 𝘀𝗶𝗴𝗻𝘀 𝗼𝗳 𝗽𝗵𝗲𝗻𝗼𝘁𝘆𝗽𝗶𝗰 𝗶𝗻𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 long before traditional assays As cell therapies, biologics, and engineered cell lines grow more complex, 𝗺𝗼𝗿𝗽𝗵𝗼𝗹𝗼𝗴𝘆 𝗶𝘀 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗮𝗻 𝗶𝗻𝗱𝗶𝘀𝗽𝗲𝗻𝘀𝗮𝗯𝗹𝗲 𝗹𝗮𝘆𝗲𝗿 𝗼𝗳 𝗤𝗖. 𝗠𝗼𝗿𝗽𝗵𝗼𝗹𝗼𝗴𝘆 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗮𝗻𝗱 𝗶𝘁’𝘀 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗮 𝗻𝗲𝘄 𝗽𝗶𝗹𝗹𝗮𝗿 𝗼𝗳 𝗯𝗶𝗼𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗾𝘂𝗮𝗹𝗶𝘁𝘆. #CellLineDevelopment #Bioprocessing #CellTherapy #Biomanufacturing #QualityControl #AIinBiotech #MorphologyMatters